Enveric Biosciences
ENVB
9 hedge funds and large institutions have $623K invested in Enveric Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 14 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.05% more ownership
Funds ownership: 0% → 0.05% (+0.05%)
57% less funds holding
Funds holding: 21 → 9 (-12)
69% less capital invested
Capital invested by funds: $1.99M → $623K (-$1.37M)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$373K |
| 2 |
BlackRock
New York
|
+$144K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$47.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$36.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$563K |
| 2 |
Renaissance Technologies
New York
|
-$234K |
| 3 |
Millennium Management
New York
|
-$49K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$48K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$43K |
ENVB Hedge Fund Activity: Q3 2022 in Review
9 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q3 2022, worth a combined $623K — down 69% from $1.99M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ENVB and 2 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was AdvisorShares Investments, adding an estimated $373K. The largest seller was Hudson Bay Capital Management, cutting an estimated $563K.
- 9 institutional investors held Enveric Biosciences (ENVB) as of Q3 2022, down from 21 in Q2 2022.
- Funds reported $623K of Enveric Biosciences stock for Q3 2022, down 69% quarter-over-quarter.
- 2 funds opened new Enveric Biosciences positions in Q3 2022 and 14 closed out, a net change of -12 holders.
- The largest Enveric Biosciences buyer in Q3 2022 was AdvisorShares Investments, an estimated $373K added.
- The largest Enveric Biosciences seller in Q3 2022 was Hudson Bay Capital Management, an estimated $563K sold.
Based on aggregated 13F filings for Q3 2022.